Skip to Content
Merck

L-arginine attenuates oxidative stress condition during cardiomyopathy.

Indian journal of biochemistry & biophysics (2013-06-01)
Pratima Tripathi, Shivani Pandey
ABSTRACT

Increased production of oxygen free radicals and decreased oxidant capacity occur in coronary artery diseases (CAD) This pro-oxidant shift in intracellular redox state may induce cell death by either direct cell membrane damage by lipic peroxidation or apoptosis through activation of transcription factors. These changes occur not only in cardiomyocytes, bu also in cardiac sympathetic nerves, which are very sensitive to oxidative damage. Patients with heart failure encountel reduced peripheralblood flow at rest, during exercise and in response to endothelium-dependentvasodilators. Current treatments of cardiomyopathy, a degenerative condition of the myocardium frequently associated with heart failure have done little to enhance patient survival. Decreased myocardial contractility and altered regulation of peripheral circulation along with oxidative conditions are important contributors to the symptoms and prognosis of the disease process. Nitric oxide formed from L-arginine (2-amino-5 guanidinovaleric acid) metabolism in endothelial cells contributes to regulation of blood flow under these conditions. L-Arginine is the precursor of nitric oxide, an endogenous messenger molecule involved in a variety of endothelium-mediated physiological effects in the vascular system. In the present study, we investigated the effect of oral administration of L-arginine (3 g/day) on the intracellular redox status of the patients of ischemic cardiomyopathy aged 45-60 yrs. The enzymatic and non-enzymatic antioxidant parameters like superoxide dismutase, catalase, total thiols (TSH) and ascorbic acid along with pro-oxidant parameters, such as xanthine oxidase, as well as index of oxidative stress as protein carbonyl content and malondialdehyde (a marker of lipid peroxidation) were investigated in the plasma and RBC lysate. L-Arginine (3 g/day) administration was found to improve the levels of these parameters in the patients and regulate the blood flow, as evident by the improved blood pressure of the patients. Thus, it is inferred that L-arginine attenuates the oxidative stress conditions along with maintaining the blood pressure rate of patients suffering from cardiomyopathy.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
L-Ascorbic acid, FCC, FG
Sigma-Aldrich
(+)-Sodium L-ascorbate, BioXtra, ≥99.0% (NT)
Sigma-Aldrich
L-Ascorbic acid, 99%
Sigma-Aldrich
L-Ascorbic acid, puriss. p.a., ACS reagent, reag. ISO, Ph. Eur., 99.7-100.5% (oxidimetric)
Sigma-Aldrich
L-Ascorbic acid, powder, suitable for cell culture, γ-irradiated
Sigma-Aldrich
L-Ascorbic acid, reagent grade
Sigma-Aldrich
L-Ascorbic acid, reagent grade, crystalline
Sigma-Aldrich
L-Ascorbic acid, BioXtra, ≥99.0%, crystalline
Supelco
L-Ascorbic acid, analytical standard
Sigma-Aldrich
L-Ascorbic acid, ACS reagent, ≥99%
Sigma-Aldrich
L-Ascorbic acid, puriss. p.a., ≥99.0% (RT)
Supelco
Sodium ascorbate, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
L-Ascorbic acid, certified reference material, TraceCERT®, Manufactured by: Sigma-Aldrich Production GmbH, Switzerland
Sigma-Aldrich
L-Arginine, 99%, FCC, FG
Supelco
Ascorbic Acid, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
L-Arginine, BioUltra, ≥99.5% (NT)
Sigma-Aldrich
Catalase from bovine liver, powder, suitable for cell culture, 2,000-5,000 units/mg protein
Sigma-Aldrich
L-Arginine, reagent grade, ≥98%
Sigma-Aldrich
Xanthine Oxidase from bovine milk, Grade IV, ammonium sulfate suspension, ≥0.1 units/mg protein
Sigma-Aldrich
Xanthine Oxidase from bovine milk, Grade III, ammonium sulfate suspension, ≥0.8 units/mg protein
Sigma-Aldrich
Xanthine Oxidase from bovine milk, Grade I, ammonium sulfate suspension, ≥0.4 units/mg protein
Sigma-Aldrich
Xanthine Oxidase from bovine milk, lyophilized powder, 0.4-1.0 units/mg protein
Sigma-Aldrich
Catalase from bovine liver, lyophilized powder, 2,000-5,000 units/mg protein
Ascorbic acid, European Pharmacopoeia (EP) Reference Standard